Tracked to date: 0 recalls, 0 warning letters, 0 rulemaking actions, and 0 FDA statements involving GLP-1 medications, as of July 17, 2026. Every count links to an FDA primary source above.
Shortage Update
FDA Drug Shortage Database Lists Semaglutide Injection Status as Resolved
As of July 15, 2026, FDA's Drug Shortages database shows the shortage status for semaglutide as "Resolved," across three database records. A resolved status means FDA has determined that supply is meeting or exceeding demand for the drug.
What this meansShortage status matters beyond the pharmacy counter: compounded versions of an FDA-approved drug are generally restricted when the drug is no longer in shortage, so this status is a key question to raise with any provider still offering compounded semaglutide.
FDA Drug Shortage Database Shows No Current Shortage Records for Tirzepatide
As of July 15, 2026, FDA's Drug Shortages database returns no shortage records for tirzepatide. That means tirzepatide does not currently appear on FDA's shortage list in any status.
What this meansWith no shortage on FDA's books, bulk compounding of tirzepatide copies is generally restricted — worth knowing when evaluating providers that market compounded tirzepatide.